Loading...

CTI BioPharma Corp.

CTIC•NASDAQ
HealthcareBiotechnology
$9.10
$0.005(0.06%)

CTI BioPharma Corp. (CTIC) Stock Overview

Explore CTI BioPharma Corp.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for CTICStats details for CTIC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CTICAnalyst Recommendations details for CTIC are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.

CEO

Dr. Adam R. Craig M.B.A., M.D., Ph.D.

Employees

127

Headquarters

3101 Western Avenue, Seattle, WA

Founded

1997

Frequently Asked Questions